Physician profile
Dione R Rowe
NPI 1174862924
$152,150.26
in general payments reported to CMS, 2019-2025
22 companies · $59K in 2025
The $59K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,516 · 2022: $19K · 2023: $38K · 2024: $32K · 2025: $59K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $84K · Consulting Fee: $20K · Travel and Lodging: $18K · Food and Beverage: $6,117 · Education: $3.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $83,765.00 |
| Consulting Fee | $20,246.00 |
| Travel and Lodging | $18,251.85 |
| Food and Beverage | $6,116.63 |
| Education | $3.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $95,283.64 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $54,606.70 | 2021-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $413.73 | 2021-2024 | Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $408.44 | 2021-2025 | Caplyta |
| Abbvie INC. | $290.91 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $219.52 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Ironshore Pharmaceuticals INC. | $157.58 | 2022-2024 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $156.01 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $109.07 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $71.09 | 2025 | Cobenfy |
| Tris Pharma INC | $70.13 | 2021-2024 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $67.51 | 2024-2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $58.01 | 2021 | |
| Collegium Pharmaceutical, INC. | $55.94 | 2025 | Jornay Pm |
| Acadia Pharmaceuticals INC | $36.43 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $29.89 | 2022-2023 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $27.26 | 2023-2024 | Trintellix |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.93 | 2023 | Aplenzin |
| Sunovion Pharmaceuticals INC. | $20.63 | 2022 | |
| Avanir Pharmaceuticals, INC. | $14.66 | 2021 | |
| Novo Nordisk INC | $14.62 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dione Rowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.